31 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26258602	39	Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3.	Pfizer Inc
26218650	41	Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes.	Korea Research Institute of Chemical Technology
25897973	29	Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors.	Takeda Pharmaceutical Co., Ltd
24900877	107	Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.	Merck Research Laboratories
24618302	49	Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors.	Merck Research Laboratories
24670009	65	Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.	Amgen Inc
23871442	88	Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.	Pfizer Inc
23810496	31	Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.	Korea Research Institute of Chemical Technology
23541669	92	Identification and design of a novel series of MGAT2 inhibitors.	AstraZeneca
23317570	42	Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors.	Merck Research Laboratories
23116186	68	Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).	AstraZeneca
22263872	15	Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.	Abbott Laboratories
24900485	13	Intestinally Targeted Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors Robustly Suppress Postprandial Triglycerides.	TBA
24900321	10	Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.	TBA
22217874	49	Design and synthesis of potent carboxylic acid DGAT1 inhibitors with high cell permeability.	Prosidion Ltd
21413799	63	Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.	Hoffmann-La Roche Inc
29986142	21	Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).	TBA
31930920	69	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.	Terns Pharmaceuticals
26561979	42	Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors.	Merck & Co., Inc.
29456796	51	Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1.	GlaxoSmithKline
29699923	47	Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.	WuXi AppTec (Shanghai) Co. Ltd
28820267	4	Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.	Merck & Co. Inc
28498655	13	Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans.	Novartis Institutes for BioMedical Research
19334715	10	Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease.	CNRS
16325401	25	Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.	Vernalis (R&D) Ltd
11708910	42	Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action.	National Institutes of Health